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CLINICAL RESEARCH ARTICLE
Trauma-focused treatment outcome for complex PTSD patients: results of an 
intensive treatment programme
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aResearch Department, PSYTREC, Bilthoven, The Netherlands; bBehavioural Science Institute (BSI), Radboud University Nijmegen, 
Nijmegen, The Netherlands; cAcademic Centre for Dentistry Amsterdam (ACTA), University of Amsterdam and VU University Amsterdam, 
Amsterdam, The Netherlands; dSchool of Psychology, Queen’s University, Belfast, UK; eInstitute of Health and Society, University of 
Worcester, Worcester, UK
ABSTRACT
Background: Complex PTSD (CPTSD) has been incorporated in the 11th edition of the 
International Classification of Diseases (ICD-11) as a mental health condition distinct from 
PTSD.
Objective: The objective of the current study is to determine whether individuals classified 
as having CPTSD can benefit from an intensive trauma-focused treatment, resulting in 
decreased PTSD and CPTSD symptoms, and loss of diagnoses.
Method: Patients diagnosed with PTSD (N = 308) took part in an intensive 8-day treatment 
programme combining prolonged exposure, EMDR therapy, psycho-education, and physical 
activity. The treatment was not phase-based in that it did not contain a stabilization phase 
or skill training prior to therapy. CPTSD diagnosis was assessed by means of the 
International Trauma Questionnaire (ITQ) and PTSD diagnosis was assessed with both the 
ITQ and CAPS-5. Treatment response was measured with the CAPS-5, PCL-5, and ITQ.
Results: Symptoms of both PTSD and CPTSD significantly decreased from pre- to post- 
treatment resulting in a significant loss of CAPS-5 based PTSD (74.0%) and ITQ-based PTSD 
and CPTSD diagnoses (85.0% and 87.7%, respectively). No adverse events occurred in terms 
of suicides, suicide attempts, or hospital admissions.
Conclusions: The results are supportive of the notion that the majority of patients classified 
as having CPTSD strongly benefit from an intensive trauma-focused treatment for their 
PTSD.
Resultado del tratamiento centrado en el trauma para pacientes con 
TEPT complejo: resultados de un programa de tratamiento intensivo 
Antecedentes: El TEPT complejo (TEPT-C) se ha incorporado en la 11ª edición de la 
Clasificación Internacional de Enfermedades (CIE-11) como una condición de salud mental 
distinta del TEPT.
Objetivo: El objetivo del presente estudio es determinar si las personas clasificadas como 
con TEPT-C pueden beneficiarse de un tratamiento intensivo centrado en el trauma, lo que 
resulta en una disminución de los síntomas de TEPT y TEPT-C y la pérdida de diagnóstico de 
TEPT.
Método: Los pacientes diagnosticados con TEPT (N = 308) participaron en un programa de 
tratamiento intensivo de 8 días que combina exposición prolongada, terapia EMDR, 
psicoeducación y actividad física. El tratamiento no se dividió en fases, ya que no 
contenía una fase de estabilización o entrenamiento de habilidades antes de la terapia. El 
diagnóstico de TEPT-C se evaluó mediante el Cuestionario Internacional de Trauma (ITQ por 
sus siglas en ingles) y el diagnóstico de TEPT se evaluó tanto con el ITQ como con CAPS-5. 
La respuesta al tratamiento se midió con CAPS-5, PCL-5 e ITQ.
Resultados: los síntomas de TEPT y TEPT-C disminuyeron significativamente del pretrata-
miento al postratamiento, lo que resultó en una pérdida significativa del diagnóstico de 
TEPT basado en CAPS-5 (74.0%) y diagnósticos de TEPT y TEPT-C basados en ITQ (85.0 
y 87.7%, respectivamente). No se produjeron eventos adversos en términos de suicidios, 
intentos de suicidio o ingresos hospitalarios.
Conclusiones: Los resultados apoyan la noción de que la mayoría de los pacientes clasifi-
cados con TEPT-C se benefician significativamente de un tratamiento intensivo centrado en 
el trauma para su TEPT.
聚焦创伤疗法对于复杂性PTSD患者的治疗结果:强化治疗方案的结果 
背景：复杂性PTSD (CPTSD) 已作为不同于PTSD的精神健康疾病, 被纳入《国际疾病分类》 
第十一次修订版 (ICD-11) 。
目的：本研究旨在确定被归类为患有CPTSD的个体是否可以从聚焦创伤强化治疗中受益, 
从而减轻PTSD和CPTSD症状, 且不再符合诊断。
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HIGHLIGHTS
• The majority, over 85%, of 
the patients diagnosed with 
Complex PTSD lost their 
diagnosis after 8 days of 
intensive trauma-focused 
treatment.  
• Complex PTSD patients can 
benefit from trauma-focused 
treatment and should not be 
excluded.
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方法：308名被诊断患有PTSD的患者参加了一项结合延长暴露疗法, EMDR治疗, 心理教育 
和体育锻炼的8天强化治疗方案。由于治疗前不含稳定阶段或技能培训, 该治疗不是分阶 
段的。CPTSD诊断由《国际创伤问卷》 (ITQ) 评估, PTSD诊断使用ITQ和CAPS-5评估。治疗 
反应使用CAPS-5, PCL-5和ITQ测量。
结果：从治疗前到治疗后, PTSD和CPTSD症状均显著下降, 导致CAPS-5的PTSD诊断 (74.0%) 
以及ITQ的PTSD和CPTSD诊断 (分别为85.0和87.7％) 的显著减少。在自杀, 自杀未遂或住院 
方面均未发生不良事件。
结论：本结果支持以下观点, 即大多数被归类为CPTSD的患者都从针对PTSD的聚焦创伤强 
化治疗中受益匪浅。
1. Introduction
Complex post-traumatic stress disorder (CPTSD) has 
been proposed as sibling disorder to post-traumatic 
stress disorder (PTSD) and incorporated as 
a separate classification within the 11th edition of the 
International Classification of Diseases (ICD-11) 
(Maercker et al., 2013; World Health Organization, 
2018). Individuals with CPTSD are described as fulfil-
ing the diagnostic criteria for PTSD in combination 
with suffering from additional disturbances in self- 
organization (DSO), more specific problems in affect 
regulation, interpersonal relations, and a negative self- 
concept (Cloitre et al., 2012; Maercker et al., 2013).
Incorporating CPTSD as a formal syndrome or men-
tal disorder is thought to increase the specificity of the 
PTSD diagnosis and to reduce overlap with other related 
conditions (Brewin et al., 2017), which is supported by 
latent class or profile analyses in various samples (Cloitre, 
Garvert, Brewin, Bryant, & Maercker, 2013; Cloitre, 
Garvert, Weiss, Carlson, & Bryant, 2014; Folke, Nielsen, 
Andersen, Karatzias, & Karstoft, 2019). However, there is 
still debate about the internal consistency and validity of 
CPTSD. For example, it has been argued that the con-
struct validity requires more evidence than can be pro-
vided by results from latent class and profile analyses 
alone (Achterhof, Huntjens, Meewisse, & Kiers, 2019; 
Ford, 2020; but see Cloitre et al., 2020). Arguments 
against incorporating CPTSD as a psychiatric diagnosis 
focus on the conflicting definitions of CPTSD (De Jongh 
et al., 2016; Resick et al., 2012), evidence regarding dif-
ferent symptom severities rather than distinct symptom 
sets (Wolf et al., 2015), and the absence of standardized 
measurement tools for the CPTSD diagnosis (De Jongh 
et al., 2016; Landy, Wagner, Brown-bowers, & Candice, 
2015). However, recent attempts have been made to 
validate self-report measures to assess CPTSD (Hyland 
et al., 2017; Karatzias et al., 2017; Shevlin et al., 2018) of 
which the 12-item version of the International Trauma 
Questionnaire (ITQ) has been proven to be a valid mea-
sure to diagnose CPTSD based on the ICD-11 (Cloitre 
et al., 2018).
In 2012 the International Society for Traumatic 
Stress Studies (ISTSS) treatment guidelines on 
CPTSD (Cloitre et al., 2011, 2012) recommended 
a phase-based treatment of CPTSD which imple-
ments a stabilization phase before starting trauma- 
focused treatment, such as prolonged exposure and 
EMDR therapy. As a response to critical analyses 
and discussions in the field about these guidelines, 
the recommendations on this topic have been 
somewhat adapted, but according to the ISTSS 
Guidelines Committee, and based upon the princi-
ple of ‘personalizing medicine’, interventions 
aimed at stability and symptom management may 
still be needed (ISTSS Guidelines Committee, 
2018).
So far, only two meta-analyses suggest that 
trauma-focused treatment, with or without phased 
interventions, could be effective for patients that 
show clinical significant symptoms associated with 
CPTSD (Karatzias et al., 2019; Mahoney, Karatzias, 
& Hutton, 2019). However, randomized controlled 
studies with head-to-head comparisons between 
phase-based and trauma-focused treatment in 
patients diagnosed with CPTSD are lacking and 
needed. To enhance our understanding about the 
efficacy of trauma-focused therapy for individuals 
with CPTSD, we investigated whether individuals 
diagnosed with CPTSD would benefit from an inten-
sive trauma-focused treatment programme without 
a stabilization phase prior to treatment that has 
been found to be effective in reducing PTSD of 
patients who have been exposed to multiple adverse 
childhood events and suffer from multiple comorbid-
ities (Van Woudenberg et al., 2018). As far as we are 
aware, we are the first to study treatment outcome of 
patients with CPTSD with the current established 
measure for CPTSD, the 12-item International 
Trauma Questionnaire (ITQ) (Cloitre et al., 2018). 
We hypothesized that symptoms of PTSD (as indexed 
by the CAPS-5 and PCL-5) and CPTSD (i.e., PTSD 
and DSO symptom severity as indexed by the ITQ) 
would significantly decrease during treatment, result-
ing in a loss of PTSD or CPTSD diagnoses. Because 
of earlier assumed difficulties and concerns about 
safety in treating CPTSD patients with trauma- 
focused therapies (Cloitre et al., 2012), we determined 
the safety of the trauma-focused treatment pro-
gramme for this target group by recording the num-
ber of adverse events (suicide, suicide attempts, or 
hospital admissions) and the proportion of patients 
that displayed reliable symptom worsening in our 
sample.
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2. Method
2. 1. Participants
Patients were regular referrals from the general 
practitioner, psychiatrist, or psychologist and treated 
from February till July 2019 at the Psychotrauma 
Expertise Centre (PSYTREC), a mental health-care 
centre in the Netherlands. Inclusion criteria were (1) 
a PTSD diagnosis as measured with the Clinician- 
Administered PTSD Scale for DSM-5 (CAPS-5), (2) 
being at least 18 years old, (3) having sufficient 
knowledge of the Dutch language to undergo treat-
ment, and (4) did not attempt suicide in the past 3 
months. A total of 409 patients were eligible for this 
research. Of these 409 patients, 52 patients did not 
give informed consent, 3 patients did not complete 
treatment and 46 patients missed an ITQ post-treat-
ment score (see Figure 1). In total, 308 patients were 
included in the study with a mean age of 41.26 
(SD = 12.70, age range 18–71, 77.6% female). 
Ethical exemption was assigned by the Medical 
Ethics Review Committee of the VU University 
Medical Centre (registered with the US Office for 
Human Research Protections (OHRP) as 
IRB00002991, FWA number FWA00017598) and 
written informed consent was obtained for using 
the data for scientific research purposes after the 
patients were informed about the study. The 
research information was given during the first 
intake session and patients had 1 week of considera-
tion time. There were no additional advertisements 
or recruiting procedures.
2. 2. Procedure
Two intake sessions preceded treatment. During the 
first, the Clinician-Administered PTSD Scale for 
DSM-5 (CAPS-5; Boeschoten et al., 2018; Weathers 
et al., 2017), Life Events Checklist for DSM-5 (LEC-5; 
Weathers et al., 2013) and Mini International 
Neuropsychiatric Interview (MINI; Lecrubier et al., 
1997; Overbeek, Schruers, & Griez, 1999) were admi-
nistered by trained psychologists. In between intakes 
1 and 2, participants filled out the International 
Trauma Questionnaire (ITQ; Cloitre et al., 2018; 
Eidhof, Ter Heide, Boeschoten, & Olff, 2018) and 
PTSD Checklist (PCL-5; Blevins, Weathers, Davis, 
Witte, & Domino, 2015; Boeschoten, Bakker, 
Jongedijk, & Olff, 2014) through a web-based 
Routine Outcome Monitoring tool. During the total 
8 days of treatment, participants were asked to fill out 
the PCL-5 at the beginning of the first therapy session 
on a daily basis. Nine days after the last treatment 
session, the post-treatment CAPS-5 measurement 
was administered at our clinic, and participants 
were asked to fill out post-treatment measurements 
of the ITQ and PCL-5 online.
2. 3. Treatment
The intensive trauma-focused treatment format con-
sisted of two consecutive weeks, with 4 days of treat-
ment each week, in which patients went home for the 
weekend in between (De Jongh et al., 2020; Van 
Toorenburg et al., 2020; Van Woudenberg et al., 
2018; Voorendonk, Sanches, De Jongh, & Van 
Minnen, 2019; Wagenmans, Van Minnen, Sleijpen, 
& De Jongh, 2018; Zoet, Wagenmans, Van Minnen, 
& De Jongh, 2018). The intensive treatment pro-
gramme is developed to treat patients suffering from 
severe PTSD and is specifically designed to reduce the 
drop-out rates for PTSD patients. See Van 
Woudenberg et al. (2018) for detailed information 
about the treatment programme. During their treat-
ment, patients stayed at the clinic. The inpatient 
treatment format was used for practical reasons 
such as to reduce travel time and to enable patients 
to follow the tight morning to evening schedule on 
treatment days. Treatment commenced without 
a prior preparation or stabilization phase and 
Figure 1. Flow chart participants. CAPS = Clinician-Administered PTSD Scale. ITQ = International Trauma Questionnaire. 
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consisted of 90 minutes of individual prolonged 
exposure (PE) in the morning and 90 minutes of 
individual eye movement desensitization and repro-
cessing (EMDR) therapy in the afternoon. PE was 
delivered according to a modified version of the pro-
tocol principles described by Foa, Hembree, and 
Rothbaum (2007). Patients did not receive audio 
recordings of their sessions so that PE fitted the 
intensive treatment format and tight schedule. 
EMDR therapy was delivered according to the 
Dutch EMDR therapy protocol by De Jongh and 
Ten Broeke (2013), which was based on the work of 
Shapiro (2018). Both PE and EMDR therapies were 
delivered by psychologists who had a master’s degree 
in clinical psychology and were trained in PE and 
EMDR therapy. The rationale for combining PE and 
EMDR therapy lies in the notion that these therapies 
may indeed share some commonalities (such as focus 
on trauma, Schnyder et al., 2015), but might have 
different underlying mechanisms (Lee, Taylor, & 
Drummond, 2006). Therefore, it is plausible that 
these treatments could enhance each other, and that 
combining those two effective treatments might lead 
to more optimal results. Furthermore, a therapist 
rotation model was used, in which each treatment 
session was delivered by a different psychologist. It 
is thought that ‘therapist rotation’ improves the treat-
ment adherence of therapists and decreases thera-
pists’ fear and avoidance behaviour, which is 
supported by explorative data (Van Minnen et al., 
2018).
In between the trauma-focused treatment sessions, 
patients took part in a physical activity and psycho- 
education programme, offered in a group setting. The 
physical activities consisted of in- and outdoor activ-
ities of varying intensity such as mountain biking and 
walking. The purpose of psycho-education was 
mainly to inform patients on PTSD-related topics, 
such as symptoms, triggers, and avoidance beha-
viours but also on the various components of the 
programme, with room for discussions. It is impor-
tant to note that no exercises nor skills training 
regarding emotion regulation, relaxation, or ground-
ing were offered during these psycho-education 
sessions.
2. 4. Measures
To establish the PTSD diagnosis based on the DSM-5 
(American Psychiatric Association, 2013) and mea-
sure the change in severity of PTSD symptoms, the 
Dutch version of the CAPS-5 (Boeschoten et al., 
2018) was used at pre- and post-treatment. The 
CAPS-5 is a diagnostic interview that assesses the 
four DSM-5 PTSD-related domains: re-experiencing 
(B), avoidance (C), negative alterations in cognition 
and mood (D), and alterations in arousal and 
reactivity (E). The CAPS-5 consists of 20 items 
about the frequency and intensity of PTSD symptoms 
that are answered on a 5-point Likert scale ranging 
from 0 (absent) to 4 (extreme/incapacitating). 
According to the CAPS-5 scoring rule (SEV2 rule), 
a symptom is present whenever the severity rating, 
after assessing both frequency and intensity rate, is 
scored to be 2 (moderate) or higher. To diagnose 
PTSD, the SEV2 rule in combination with the 
DSM-5 algorithm was used (Boeschoten et al., 2018; 
Weathers et al., 2017). The total severity score is 
calculated by summing up item 1 to 20, with an 
overall scoring range between 0 and 80. At pre-treat-
ment, the CAPS-5 month version was administered, 
whereas the CAPS-5 week version was used at post- 
treatment. The CAPS-5 Dutch version has good 
internal consistency and reliability (Boeschoten 
et al., 2018).
To establish the PTSD and CPTSD diagnoses 
based on the ICD-11, and measure the change in 
the severity of PTSD and DSO symptoms, the 
Dutch version of the ITQ was used at pre- and 
post-treatment (Cloitre et al., 2018; Eidhof et al., 
2018). The ITQ is a self-report measure and consists 
of 12 items with a 5-point Likert scale ranging from 0 
(not at all) to 4 (extremely). The ITQ consists of three 
symptom clusters referring to PTSD (re-experiencing, 
avoidance and sense of threat) and three additional 
symptom clusters referring to DSO (affective dysre-
gulation, disturbances in relationships, and negative 
self-concept). The CPTSD diagnosis is constructed as 
a combination of all PTSD symptom clusters and all 
DSO symptom clusters. Every symptom cluster con-
sists of two symptoms and only severity scores of 2 or 
higher are used to indicate a symptom. For both 
PTSD and CPTSD diagnosis, the endorsement of 
one of two symptoms from each symptom cluster 
and an additional functional impairment are 
required. A patient cannot receive both PTSD and 
CPTSD diagnoses. The total severity of PTSD and 
DSO symptom scores is calculated by, respectively, 
summing up item 1 to 6 and 7 to 12, with a total ITQ 
score ranging between 0 and 48 (PTSD+DSO). In 
addition, the three DSO symptom clusters separately 
have an overall scoring range of 0 to 8, with a total 
DSO symptom score ranging between 0 and 24. At 
pre-treatment, the ITQ month version was adminis-
tered, whereas an ITQ week version was used at post- 
treatment. The previous versions of the ITQ have 
been shown to be reliable and valid measures of 
PTSD and DSO (Hyland et al., 2017; Karatzias 
et al., 2017; Shevlin et al., 2018), and the currently 
used 12-item version is recently demonstrated to be 
a valid measure to diagnose PTSD and CPTSD based 
on the ICD-11 (Cloitre et al., 2018).
To assess the change in PTSD symptom severity 
during treatment, the Dutch version of the PTSD 
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Checklist (PCL-5; Boeschoten et al., 2014) was used 
as a self-report measure at baseline, on each of the 8 
treatment days and at post-treatment. The PCL-5 is 
based on the PTSD diagnosis of the DSM-5 and 
consists of 20 items with a 5-point Likert scale ran-
ging from 0 (not at all) to 4 (extremely). The total 
severity score is calculated by summing up item 1 to 
20, with an overall scoring range between 0 and 80. 
The PCL-5 has high internal consistency and good 
validity (Blevins et al., 2015).
The Dutch version of The Life Events Checklist for 
DSM-5 (LEC-5) (Weathers et al., 2013) was used to 
assess the type of traumatic events that patients had 
experienced at baseline. This self-report measure con-
sists of 17 items on which the patients can score 
whether or not they encountered the traumatic events.
The Dutch version of the Mini International 
Neuropsychiatric Interview was used (MINI) 
(Overbeek et al., 1999) to establish a diagnosis for 
the possible presence of comorbid disorders and 
assess current suicidal risk. It is a reliable and well- 
validated structured diagnostic interview to establish 
DSM-IV diagnosis (Lecrubier et al., 1997). All scores 
are obtained as a dichotomous score (yes or no), and 
suicidal risk was categorized as ‘no risk’, ‘low’, ‘mod-
erate’, and ‘high’.
2. 5. Statistical analysis
For all statistical analysis, IBM SPSS Statistics version 25 
was used and the level of significance was set at a =.05 
(two-sided). To check whether the group that had 
a missing ITQ post-treatment score and was excluded 
from analysis (n = 46) differed significantly from the 
completers sample (n = 308) on gender, mean age, 
suicide risk, comorbidity, type of trauma, ITQ pre- 
scores, pre- and post-scores of the CAPS-5 and PCL-5, 
independent sample t-tests and chi-square tests were 
conducted. Since the assumptions for mixed-design 
ANOVA were violated (normality, homogeneity of 
variances), non-parametric options or Welch– 
Satterthwaite adjusted degrees of freedom were used 
when needed in the ITQ-PTSD and ITQ-CPTSD 
group separately. Wilcoxon signed-rank tests were 
administered on CAPS-5 and PCL-5 scores at pre- 
and post-treatment, and Mann–Whitney tests were 
administered on the CAPS-5 and PCL-5 symptom dif-
ference scores (post-pre) to compare the change in the 
two groups. Friedman tests were used on the PCL-5 
scores during the 8 days of treatment for both groups 
separately. Regarding the ITQ scores, paired sample 
t-tests were used on the ITQ total score and ITQ DSO 
score at pre- and post-treatment. Independent sample 
t-tests were used to compare the change on the ITQ 
total score and ITQ DSO score (post-pre) in the two 
groups. Wilcoxon signed-rank tests were administered 
on the ITQ PTSD symptoms and the three ITQ DSO 
symptom cluster scores at pre- and post-treatment, and 
a Mann–Whitney test was administered on the ITQ 
PTSD symptom difference scores (post-pre) to compare 
the change in the two groups. Clinical relevant symp-
tom change on the CAPS-5 and ITQ at post-treatment 
was assessed by looking at the percentage that lost 
a PTSD or CPTSD diagnosis. Loss of PTSD diagnosis 
on the CAPS-5 was defined as no longer fulfiling the 
SEV2 rule in combination with the DSM-5 algorithm 
(Boeschoten et al., 2018; Weathers et al., 2017). Loss of 
PTSD diagnosis on the ITQ was defined as no longer 
endorsement of at least one symptom per PTSD symp-
tom cluster or functional impairment. Loss of CPTSD 
diagnosis on the ITQ was defined as no longer endorse-
ment of one symptom per DSO symptom cluster or 
functional impairment, or not fulfiling the ITQ-based 
PTSD diagnosis anymore. To determine whether 
patients experienced symptom improvement or wor-
sening beyond what could be attributed to measure-
ment error, the reliable change (RC) index was 
calculated for the CAPS-5 and PCL-5. Pooled standard 
deviations of pre- and post-measurements were used 
(Lancaster et al., 2019) in combination with test–retest 
reliability information from previous research (Blevins 
et al., 2015; Weathers et al., 2017). Symptom improve-
ment and worsening scores above 14.05 on the CAPS-5 
and above 15.89 on the PCL-5 were characterized as 
reliable changes.
3. Results
The sample of 308 patients consisted of patients suf-
fering from severe PTSD reflected by the high CAPS- 
5 severity scores, high rates of sexual (80.8%) and 
physical abuse (92.5%), and elevated suicide risks 
(74.3%). No differences between the excluded 
(n = 46) and completers sample (n = 308) could be 
detected on gender, suicide risk, comorbidity, type of 
trauma, ITQ pre-scores, PCL-5 pre- and post-scores, 
and CAPS-5 pre-scores (all ps >.154). Conversely, the 
excluded sample was significantly younger (p = .008) 
and had lower CAPS-5 post-scores (p = .019) than the 
completers sample.
All 308 included patients had a PTSD diagnosis 
based on the CAPS-5 at baseline. Of these 308 
patients, 203 patients (65.9%) met the diagnostic cri-
teria of CPTSD (ITQ-CPTSD group), and 60 patients 
(19.5%) met the diagnostic criteria of PTSD (ITQ- 
PTSD group). The remaining 45 patients (14.6%) did 
not meet the criteria for CPTSD or PTSD diagnosis 
measured with the ITQ. For patient flow, see Figure 1 
and for sample characteristics, see Table 1. In line 
with previous studies, patients with CPTSD (ITQ- 
CPTSD group) more often reported a history of sex-
ual abuse and showed a higher rate of comorbidity 
and elevated suicide rates in comparison to PTSD 
patients (ITQ-PTSD group). Of all patients that 
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showed a history of physical or sexual abuse, most 
patients (85.1%) had suffered from multiple, repeated 
traumas. In addition, 57.7% reported sexual abuse 
during childhood (before age 12).
3. 1. Change in PTSD symptom severity (CAPS-5 
and PCL-5)
A significant decrease in CAPS-5 scores (Z = −6.60, 
p < .001, Cohen’s d = 1.51) and PCL-5 scores 
(Z = −6.71, p < .001, Cohen’s d = 1.55) from pre- 
to post-treatment in the ITQ-PTSD group was 
found. In addition, a significant decrease in 
CAPS-5 scores (Z = −12.19, p < .001, Cohen’s 
d = 1.52) and PCL-5 scores (Z = −12.19, p < .001, 
Cohen’s d = 1.53) from pre- to post-treatment in 
the ITQ-CPTSD group was found. Pre- to post- 
treatment decline of CAPS-5 scores were not sig-
nificantly different between the groups 
(U = 5445.00, p = .213), but the decline in PCL-5 
scores from pre- to post-treatment was significantly 
stronger in the ITQ-CPTSD group compared to the 
ITQ-PTSD group (U = 5017.50, p = .043). These 
results are presented in Figure 2. Furthermore, 
a significant decrease in PCL-5 scores during the 
8 days of treatment was found for both the ITQ- 
PTSD group (χ2(7) = 230.57, p < .001) and the 
ITQ-CPTSD group (χ2(7) = 791.21, p < .001; see 
Figure 2).
3. 2. Change in PTSD and DSO symptom severity 
(ITQ)
A significant decrease in ITQ total scores was found 
from pre- to post-treatment in the ITQ-PTSD (t 
(59) = 14.59, p < .001, Cohen’s d = 1.88) and ITQ- 
CPTSD group (t(202) = 28.17, p < .001, Cohen’s 
d = 1.98). The decline in ITQ total scores from pre- to 
post-treatment was significantly stronger in the ITQ- 
CPTSD group compared to the ITQ-PTSD group (t 
(261) = 3.01, p = .003). A significant decrease in ITQ 
PTSD symptom scores was found from pre- to post- 
treatment in the ITQ-PTSD (Z = −6.66, p < .001, 
Cohen’s d = 1.53) and ITQ-CPTSD group 
(Z = −12.25, p < .001, Cohen’s d = 1.53). Furthermore, 
a significant decrease in ITQ DSO symptom scores was 
found from pre- to post-treatment in the ITQ-PTSD (t 
(59) = 9.70, p < .001, Cohen’s d = 1.25) and ITQ-CPTSD 
Table 1. Baseline sample characteristics for the total sample 
and the ITQ-PTSD and ITQ-CPTSD groups separately.
Total 
n = 308
ITQ-PTSD 
n = 60
ITQ-CPTSD 
n = 203
n (%) n (%) n (%)
Trauma exposure 
Sexual abuse* 
Physical abuse 
Natural disasters and 
severe accidents
249 (80.8) 
285 (92.5) 
208 (67.5)
43 (71.7) 
54 (90.0) 
39 (65.0)
175 (86.2) 
190 (93.6) 
135 (66.5)
Comorbidity 
Depressive 
disorders*** 
Anxiety disorders**
166 (53.9) 
137 (44.5)
22 (36.7) 
16 (26.7)
129 (63.5) 
102 (50.2)
Suicide risk 
No** 
Low 
Medium 
High**
79 (25.6) 
111 (36.0) 
48 (15.6) 
70 (22.7)
23 (38.3) 
23 (38.3) 
9 (15.0) 
5 (8.3)
40 (19.7) 
75 (36.9) 
35 (17.2) 
53 (26.1)
*p <.05, **p <.01, ***p <.001; significant differences between ITQ-PTSD 
and ITQ-CPTSD. 
Figure 2. Mean (a) CAPS-5 and (b) PCL-5 scores at pre- and post-treatment and (c) mean PCL-5 scores during treatment for 
patients with ITQ-CPTSD and ITQ-PTSD diagnosis. *p <.05, **p <.01, ***p <.001; a significant difference in decline between ITQ- 
CPTSD and ITQ-PTSD group. Error bars represent standard error of the mean (s.e.m.). 
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group (t(202) = 21.31, p < .001, Cohen’s d = 1.50). There 
was no significant difference in pre- to post-treatment 
decline of ITQ PTSD symptom scores between the 
groups (U = 5818.00, p = .599). However, the decline 
in ITQ DSO symptom scores from pre- to post-treat-
ment was significantly stronger in the ITQ-CPTSD 
group compared to the ITQ-PTSD group (t 
(139.17) = 5.56, p < .001). These results are presented 
in Figure 3. Means and standard deviations for the three 
DSO symptom clusters per ITQ-PTSD or ITQ-CPTSD 
group are presented in Table 2, which shows significant 
decreases in all clusters (all ps <.001) with moderate to 
large effect sizes.
3. 3. Effect of treatment on loss of diagnoses and 
symptom improvement
Based on the CAPS-5, 228 patients (74.0%) did not fulfil 
the diagnostic criteria of PTSD at post-treatment and 
thus lost their PTSD diagnosis. Also, of those who could 
be diagnosed with PTSD based on the ITQ at baseline 
(n = 60), 51 patients (85.0%) lost their ITQ-PTSD 
diagnosis at post-treatment. Likewise, of those who 
could be diagnosed with CPTSD based on the ITQ at 
baseline (n = 203), 178 patients (87.7%) lost their ITQ- 
CPTSD diagnosis at post-treatment (see Figure 4). 
Overall, 244 patients (79.2%) showed reliable symptom 
improvement on the CAPS-5 from pre- to post-treat-
ment (RC index > 14.05), with on average a decrease of 
32.10 points (SD = 9.30). In the ITQ-PTSD group, 
80.0% showed reliable improvement on the CAPS-5, 
in the ITQ-CPTSD group 76.4%. In addition, 263 
patients (85.4%) showed reliable symptom improve-
ment on the PCL-5 from pre- to post-treatment (RC 
index > 15.89), with on average a decrease of 39.53 
points (SD = 12.63). In the ITQ-PTSD group, 85.0% 
showed reliable improvement on the PCL-5, in the 
ITQ-CPTSD group 84.7%.
3. 4. Safety and symptom worsening
There were no adverse events monitored by the clin-
ical staff during the study time frame. None of the 
patients showed reliable symptom worsening on the 
Figure 3. Mean (a) ITQ total, (b) ITQ PTSD symptom and (c) ITQ DSO symptom scores at pre- and post-treatment for patients 
with ITQ-CPTSD and ITQ-PTSD diagnosis. *p <.05, **p <.01, ***p <.001; a significant difference in decline between ITQ-CPTSD 
and ITQ-PTSD group. Error bars represent standard error of the mean (s.e.m.).
Table 2. DSO symptom cluster scores (AD = Affect dysregula-
tion, NSC = Negative self-concept, DR = disturbed relation-
ships) at pre- and post-treatment in the ITQ-PTSD (n = 60) 
and ITQ-CPTSD group (n = 203).
Effect size
Pre Post Pre-post
Mean SD Mean SD Cohen’s d
ITQ-PTSD
AD*** 4.28 1.53 1.83 1.68 1.34
NSC*** 1.88 1.91 .85 1.59 .69
DR*** 3.85 1.96 1.80 1.88 1.27
ITQ-CPTSD
AD*** 5.42 1.40 2.55 2.16 1.34
NSC*** 6.34 1.48 2.77 2.60 1.36
DR*** 6.05 1.45 2.93 2.38 1.34
*p <.05, **p <.01, ***p <.001. 
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CAPS-5, nor on the PCL-5, during the duration of 
the study based on the RC indexes (CAPS-5 > 14.05; 
PCL-5 > 15.89).
4. Discussion
4. 1. Main findings
The results lend support to our hypothesis that symp-
toms of both PTSD and CPTSD (PTSD and DSO 
symptoms) would significantly decrease after 
trauma-focused treatment. Although CPTSD patients 
were characterized by somewhat higher severity 
scores than PTSD patients, both patient groups 
showed a strong and comparable decrease in PTSD 
and CPTSD-related symptoms from pre- to post- 
treatment. This is reflected in a significant level of 
loss of PTSD and CPTSD diagnoses (85.0% and 
87.7%, respectively) based on the International 
Trauma Questionnaire (ITQ). Further, the absence 
of adverse events and none of the patients showing 
reliable symptom worsening from pre- to post-treat-
ment support the safety of treating CPTSD patients 
with an intensive trauma-focused inpatient treatment 
programme without a stabilization phase prior to 
treatment.
To our knowledge, this is the first study to inves-
tigate an intensive trauma-focused treatment out-
come in a large sample of CPTSD patients 
(n = 203), formally established with the 12-item 
ITQ (Cloitre et al., 2018). Several findings are note-
worthy. First, while all patients were diagnosed with 
PTSD based on the CAPS-5, 14.6% did not meet the 
diagnostic criteria of PTSD based on the ICD-11 
criteria as measured with the ITQ, which is in line 
with the more strict diagnostic criteria for a PTSD 
diagnosis in the ICD-11 in comparison with the 
DSM-5. Of the patients who met a CAPS-5 PTSD 
diagnosis, a large proportion (65.9%) met the criteria 
for CPTSD based on the ITQ. This is much higher 
than the prevalence of 13% previously estimated 
before the ITQ was published (Wolf et al., 2015). 
The significant decrease in key symptoms of 
CPTSD, the large proportion of CPTSD patients 
that lost their diagnosis (87.7%), the decline in emo-
tion regulation difficulties, disturbances in interper-
sonal relationships, and increase in self-esteem, 
following intensive trauma-focused treatment, 
emphasized that we should not deter from offering 
the option of trauma-focused treatment to CPTSD 
patients. The commonly held belief that patients 
with CPTSD warrant a different treatment (e.g. sta-
bilization or skill training in the first treatment phase 
before the start of trauma-focused treatment) can be 
questioned based on our results (Cloitre et al., 2011; 
De Jongh et al., 2016).
4. 2. Limitations
Our results should be considered in light of the 
limitations of this study, the main being the uncon-
trolled nature of the study. Since there is no com-
parison with a control group that was provided with 
an a priori stabilization programme, we cannot rule 
out the possibility that additional stabilization could 
have improved treatment outcome for CPTSD 
patients even more. Besides, follow-up measure-
ments are needed in future studies, as possible dif-
ferences between trauma-focused treatment and 
phase-based treatments might only become visible 
at follow-up. Also, our treatment programme was 
provided on an in-patient basis, so that it is 
unknown whether these results would transfer to 
outpatient treatment programmes. Furthermore, 
Figure 4. Number of patients with a PTSD diagnosis on CAPS-5 and with a PTSD or CPTSD diagnosis on ITQ at pre- and post- 
treatment. The percentage reflects the loss of diagnoses. 
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the pre- and post-measurements of the PTSD and 
CPTSD symptoms covered different time-frames 
(month vs. week) which could have influenced the 
results, even though strong reductions of symptoms 
and loss of diagnoses were found. Finally, despite 
the fact that the ITQ is currently considered an 
established measure to diagnose a CPTSD diagnosis, 
classifying individuals based on a self-report mea-
sure instead of a clinician-rated instrument such as 
a clinical interview strongly questions the reliability 
and validity of the diagnosis (Cloitre et al., 2018).
4. 3. Implications
In conclusion, the results of the present study support 
the notion that the majority of patients with CPTSD 
can benefit from intensive trauma-focused psy-
chotherapy. Although a small percentage of patients 
remained fulfiling the criteria of CPTSD after treat-
ment (12.3%), none of the patients showed reliable 
symptom worsening on both self-report and clinical 
interview measures from pre- to post-treatment. This 
suggests that intensive trauma-focused treatment 
does not pose significant risks for patients with 
CPTSD and that we should not prevent CPTSD 
patients from undergoing evidence-based trauma- 
focused treatment. The patients that did not recover, 
may be in need of a longer treatment programme, 
which would be in line with previous studies showing 
that adding more sessions can enhance treatment 
results (Foa et al., 2005). Nevertheless, future con-
trolled research on optimal treatments for all CPTSD 
patients and support for intensive trauma-focused 
treatment programmes outside the clinical setting 
are required.
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